Results 91 to 100 of about 27,778 (225)
Impending anterior ischemic optic neuropathy with elements of retinal vein occlusion in a patient on interferon for polycythemia vera. [PDF]
, 2012 We describe the course and likely pathophysiology of impending anterior ischemic optic neuropathy (AION) and retinal vein occlusion in a 56-year-old man with polycythemia vera managed with interferon alpha for 2 years.
Hirsch, Louis K +2 more
core +1 more source
Annals of Hepatology, 2010 There are no well established treatment guidelines about acute hepatitis C (AHC), leaving physicians to make several challenging decisions, such whether to treat, when to treat and what treatment regimens to use.
Paulo Roberto Lerias de Almeida
doaj +1 more source
Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis [PDF]
, 2009 Targeted immune-modulating agents are entering clinical practice in many specialties, providing novel therapeutic possibilities but introducing new potential toxicities.
Clatworthy, Menna R +4 more
core +2 more sources
Journal of Infection in Developing Countries, 2011 Interferon alpha is a molecule frequently used in the treatment of chronic hepatitis B, C, and D, with immunomodulatory and antiviral activity. It is also used in some cancer types. It has been widely claimed that interferon alpha triggers autoimmunity,
Sukran Kose +3 more
doaj +1 more source
A cost-utility analysis of different antiviral medicine regimens in patients with chronic hepatitis C virus genotype 1 infection [PDF]
, 2016 Background: Despite the introduction of new drug regimens with high effectiveness for the hepatitis C virus (HCV) patients, especially in HCV genotype 1, no cost-effectiveness study on the selection of the superior drug strategy in Iran has been ...
Alavian, Seyed Moayed +6 more
core +1 more source
Systemic Interferon Alfa in Multiple Sclerosis
Archives of Neurology, 1989 To the Editor. —We wish to comment on the conclusions reached by Panitch 1 in his follow-up study of patients treated with subcutaneous interferon alfa. Panitch notes that patients treated with interferon alfa experienced a reduction in attack frequency from 1.33 per year to 0.47 per year over a mean follow-up of four years.
Weinshenker, BG, Ebers, G
openaire +2 more sources
Brazilian Journal of Infectious DiseasesChronic hepatitis C is often a progressive, fibrotic disease that can lead to cirrhosis and other complications. The recommended therapy is a combination of interferon and ribavirin.
Kleber Prado +3 more
doaj +1 more source
Medikamentöse Therapie der chronischen Hepatitis B [PDF]
, 2018 Zusammenfassung: • Ziel: Verhinderung des Voranschreitens zur Zirrhose, resp. der Entwicklung eines hepatozellulären Karzinoms. • Aktuelle medizinische Behandlung: Interferon-alfa. • Wirksamkeit: Suppression der viralen Replikation bei 40% der Patienten,
Lavanchy, Daniel, Renner, Eberhard
core
Muir-Torre syndrome - Treatment with isotretinoin and interferon alpha-2a can prevent tumour development [PDF]
, 2000 Muir-Torre syndrome is a genodermatosis in which multiple internal malignancies are associated with cutaneous sebaceous tumours and kerato-acanthomas. A 57-year-old man presented with multiple sebaceous tumours, kerato-acanthomas, verrucous carcinoma of ...
Burgdorf, Walter H. C. +3 more
core +1 more source
Response to treatment with interferon-alpha and ribavirin in patients with chronic Hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis [PDF]
, 2006 The combined therapy with interferon alfa plus ribavirin (INF+RBV) is considered the most appropriate treatment for patients with chronic hepatitis C virus genotypes 2 and 3 in Brazil.
Conceição, Raquel D. O. +4 more
core +1 more source